DOJ subpoenas Aegerion over Juxtapid

Candace Stuart | January 10, 2014 | Cardiovascular Business | Structural Heart Disease

Aegerion Pharmaceuticals confirmed that it is under a federal magnifying glass again. The company disclosed in a financial statement that it was subpoenaed by the Department of Justice (DOJ) over its cholesterol drug, lomitapide.

The subpoena requested that the Cambridge, Mass.-based company provide documents about sales and marketing of lomitapide. Lomitapide (Juxtapid) has been approved as an adjunct to a low-fat diet and other treatments that lower lipids in patients with homozygous familial hypercholesterolemia.

In November 2013, Aegerion CEO Marc Beer received a warning letter from the FBI, which accused him of misbranding Juxtapid during appearances on a CNBC show “Fast Money.”

The company said it is cooperating with the DOJ in its investigation.

Candace Stuart, Contributor

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business

Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Related Content

Around the web